USD 0.25
(-1.15%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 43.16 Million USD | 2150.63% |
2022 | 1.91 Million USD | -47.78% |
2021 | 3.67 Million USD | -30.37% |
2020 | 5.27 Million USD | 22.13% |
2019 | 4.31 Million USD | 0.0% |
2018 | - USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | -100.0% |
2012 | 780 Thousand USD | 3.59% |
2011 | 753 Thousand USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 45.42 Million USD | 5.22% |
2024 Q2 | 47.16 Million USD | -83.51% |
2023 FY | 43.16 Million USD | 2150.63% |
2023 Q2 | 982 Thousand USD | -32.55% |
2023 Q1 | 1.45 Million USD | -24.09% |
2023 Q3 | 7.31 Million USD | 644.6% |
2023 Q4 | 43.16 Million USD | 490.36% |
2022 Q1 | 3.25 Million USD | -11.52% |
2022 FY | 1.91 Million USD | -47.78% |
2022 Q4 | 1.91 Million USD | -19.17% |
2022 Q3 | 2.37 Million USD | -15.79% |
2022 Q2 | 2.81 Million USD | -13.29% |
2021 Q1 | 4.88 Million USD | -7.32% |
2021 Q3 | 4.08 Million USD | -9.03% |
2021 Q4 | 3.67 Million USD | -10.17% |
2021 FY | 3.67 Million USD | -30.37% |
2021 Q2 | 4.49 Million USD | -8.06% |
2020 Q1 | 4.08 Million USD | -5.37% |
2020 FY | 5.27 Million USD | 22.13% |
2020 Q3 | 3.72 Million USD | -6.15% |
2020 Q4 | 5.27 Million USD | 41.76% |
2020 Q2 | 3.96 Million USD | -2.99% |
2019 Q4 | 4.31 Million USD | -5.01% |
2019 FY | 4.31 Million USD | 0.0% |
2019 Q1 | 4.98 Million USD | 0.0% |
2019 Q2 | 4.77 Million USD | -4.33% |
2019 Q3 | 4.54 Million USD | -4.72% |
2018 Q2 | - USD | 0.0% |
2018 FY | - USD | 0.0% |
2018 Q4 | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2016 Q2 | 1.23 Million USD | 0.0% |
2016 FY | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 Q4 | - USD | -100.0% |
2016 Q3 | 998 Thousand USD | -18.99% |
2015 Q1 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2013 Q4 | - USD | -100.0% |
2013 Q2 | 3.19 Million USD | 0.0% |
2013 Q1 | - USD | -100.0% |
2013 FY | - USD | -100.0% |
2013 Q3 | 311 Thousand USD | -90.28% |
2012 FY | 780 Thousand USD | 3.59% |
2012 Q4 | 780 Thousand USD | 0.0% |
2011 FY | 753 Thousand USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Editas Medicine, Inc. | 36.53 Million USD | -18.149% |
Dynavax Technologies Corporation | 256.91 Million USD | 83.198% |
Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -3.949% |
Perrigo Company plc | 4.07 Billion USD | 98.94% |
Illumina, Inc. | 2.26 Billion USD | 98.092% |
Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.876% |
Iovance Biotherapeutics, Inc. | 1 Million USD | -4216.7% |
Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.548% |
IQVIA Holdings Inc. | 14.23 Billion USD | 99.697% |
Heron Therapeutics, Inc. | 173.75 Million USD | 75.156% |
Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 98.403% |
Unity Biotechnology, Inc. | 26.99 Million USD | -59.937% |
Waters Corporation | 2.35 Billion USD | 98.167% |
Biogen Inc. | 7.33 Billion USD | 99.412% |
Sangamo Therapeutics, Inc. | 38.1 Million USD | -13.287% |
Evolus, Inc. | 126.54 Million USD | 65.888% |
Adicet Bio, Inc. | 17.7 Million USD | -143.84% |
bluebird bio, Inc. | 330.32 Million USD | 86.932% |
Esperion Therapeutics, Inc. | 540.94 Million USD | 92.02% |
FibroGen, Inc. | 170.45 Million USD | 74.675% |
Agilent Technologies, Inc. | 2.73 Billion USD | 98.422% |
Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -106.697% |
Homology Medicines, Inc. | 44.05 Million USD | 2.013% |
Geron Corporation | 85.89 Million USD | 49.747% |
Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 98.2% |
Amicus Therapeutics, Inc. | 445.05 Million USD | 90.301% |
Myriad Genetics, Inc. | 145 Million USD | 70.23% |
Viking Therapeutics, Inc. | 1.26 Million USD | -3325.952% |
Intellia Therapeutics, Inc. | 115.34 Million USD | 62.576% |
Zoetis Inc. | 6.8 Billion USD | 99.365% |
Abeona Therapeutics Inc. | 4.4 Million USD | -880.622% |
Mettler-Toledo International Inc. | 2.16 Billion USD | 98.009% |
BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 96.193% |
Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 94.66% |
Kala Pharmaceuticals, Inc. | 36.32 Million USD | -18.842% |
Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 97.03% |
Atara Biotherapeutics, Inc. | 57.87 Million USD | 25.41% |
Verastem, Inc. | 41.55 Million USD | -3.874% |
Nektar Therapeutics | 230.4 Million USD | 81.264% |
Axsome Therapeutics, Inc. | 186.37 Million USD | 76.838% |
Aclaris Therapeutics, Inc. | 3.07 Million USD | -1304.262% |
Sarepta Therapeutics, Inc. | 1.39 Billion USD | 96.91% |
OPKO Health, Inc. | 326.56 Million USD | 86.781% |
Exelixis, Inc. | 189.94 Million USD | 77.274% |
Neurocrine Biosciences, Inc. | 428.4 Million USD | 89.924% |
Corcept Therapeutics Incorporated | 151 Thousand USD | -28487.417% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 138.4 Million USD | 68.812% |
Imunon, Inc. | 1.13 Million USD | -3688.929% |
Blueprint Medicines Corporation | 774.12 Million USD | 94.424% |
Insmed Incorporated | 1.2 Billion USD | 96.415% |
Halozyme Therapeutics, Inc. | 1.49 Billion USD | 97.121% |
Agios Pharmaceuticals, Inc. | 56.98 Million USD | 24.252% |
TG Therapeutics, Inc. | 110.79 Million USD | 61.039% |
Incyte Corporation | 38.28 Million USD | -12.746% |
Emergent BioSolutions Inc. | 877.5 Million USD | 95.081% |